Amazon Made GLP-1s $25/Month — Astra Blog
What GLP-1 users actually buy
Amazon launched a national GLP-1 management program last week, putting weight loss drugs like Wegovy and Zepbound on a primary care subscription starting at $25 per month with insurance through Amazon One Medical and Amazon Pharmacy. Hims and Hers stock dropped 6% on the news.
For most Amazon sellers, the natural reaction is to scroll past it. Sellers can't list Wegovy or Zepbound on the marketplace. These are prescription drugs, and Amazon Pharmacy is the only channel for them. There's no direct market for FBA sellers in the weight loss drug itself.
That's not the story. The story is what GLP-1 users buy when they're not buying drugs.
| Behavior Shift | Change vs. Pre-GLP-1 | Direction |
|---|---|---|
| Protein consumption | Up 65% | Strong Increase |
| Fruit and vegetable consumption | Up nearly 80% | Strong Increase |
| Snack categories | Down 40 to 60% | Sharp Decline |
| Sweets, salty snacks, sugary drinks | Down across the board | Sharp Decline |
| Willingness to pay for quality health products | 80% say yes | High Intent |
Source: EY-Parthenon survey data on active GLP-1 users. ADM research for willingness-to-pay figure.
The side effects of the medication drive their own demand. Muscle loss is common, pushing demand for high-protein supplements, BCAAs, creatine, and collagen. Constipation and digestive issues drive demand for fiber, probiotics, and microbiome supplements. Hydration matters more than usual, growing the electrolyte and rehydration category. Skin elasticity changes pull spend toward beauty and personal care products focused on hydration and collagen support. B-vitamin deficiency is common with reduced food intake, so multivitamins and targeted supplementation are growing.
$25 Monthly GLP-1 subscription price with insurance via Amazon 23% Share of US food and bev sales from GLP-1 households today 35% Circana projection for that share by 2030
The cohort isn't shrinking the pie. It's reshaping it. The volume of what GLP-1 users buy drops, but the willingness to pay for quality goes up. ADM's research found that 80% of active GLP-1 users are willing to spend more on products that offer additional health benefits beyond basic nutrition.
Why Amazon's position is unique
Amazon now operates the prescription, the delivery, and the marketplace where these users buy adjacent products. No other retailer has all three. Walmart sells the drugs but doesn't have an ad platform at Amazon's scale. Hims and Ro sell the drugs but don't have a third-party marketplace.
Amazon Pharmacy is HIPAA-protected, so the prescription data itself doesn't flow into ad targeting or product recommendations. That's not the point. The point is that Amazon's retail side already sees the behavioral signature of GLP-1 users from search queries and purchase patterns: high-protein, low-sugar, electrolyte-heavy, supplement-heavy, smaller-portion. As the cohort grows, that behavioral pattern is what drives "frequently bought together" recommendations, ad targeting, and Rufus answers, regardless of what's on anyone's prescription.
The AI-driven discovery surfaces that decide what shoppers see are where this signal will compound first. You don't need prescription data. You need your listing to be structurally ready for the search behavior the cohort generates.
